Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

2 years ago

Live video webcast panel presentation on Tuesday, September 26th at 1:35 PM ETISELIN, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) --…

Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross

2 years ago

SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on…

Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer

2 years ago

Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer Collaboration…

Revolo Biotherapeutics Announces the Completion of Phase 1 Multiple Ascending Dose Clinical Trial of ‘1104

2 years ago

The positive safety profile supports dosing of ‘1104 at higher doses in upcoming Phase 2b trial in EoENEW ORLEANS and…

electroCore to Present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference

2 years ago

ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced…

NeurAxis Reports Second Quarter 2023 Financial Results

2 years ago

CARMEL, Ind., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company…

Bionano Announces Third OEM Partner has Received China NMPA Approval for DNA Isolation Products for IVD Use of OGM

2 years ago

Bionano original equipment manufacturing (OEM) partner Ecobono obtained reagent Class I registration and approval for Bionano’s DNA isolation kits for…

89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

2 years ago

–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b trial of pegozafermin– –Discussions with…

Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update

2 years ago

Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related…

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

2 years ago

Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage…